Karen Wernli

Affiliate Associate Professor, Epidemiology
Affiliate Associate Professor, Health Systems and Population Health



PhD Epidemiology, University of Washington, 2006
MS Epidemiology, University of Texas, 1998
BS Animal Physiology, University of California (San Diego), 1995



1730 Minor Ave., Suite 1600
Seattle, WA 98101
View Website »

Research Interests

Comparative effectiveness research; cancer screening and diagnostic, preventive services, methodology

Recent Publications (PubMed)

Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network.
(2023 May)
Influenza Other Respir Viruses 17(5): e13143
Tartof SY, Xie F, Yadav R, Wernli KJ, Martin ET, Belongia EA, Gaglani M, Zimmerman RK, Talbot HK, Thornburg N, Flannery B, US Flu VE Network Investigators

Evaluating reduced effectiveness after repeat influenza vaccination while accounting for confounding by recent infection and within-season waning.
(2023 Mar 17)
Bi Q, Dickerman BA, McLean HQ, Martin ET, Gaglani M, Wernli KJ, Goundappa B, Flannery B, Lipsitch M, Cobey S, US Flu Vaccine Effectiveness Network Investigators

Influenza Vaccine Effectiveness Among Children: 2011-2020.
(2023 Apr 1)
Pediatrics 151(4):
Hood N, Flannery B, Gaglani M, Beeram M, Wernli K, Jackson ML, Martin ET, Monto AS, Zimmerman R, Raviotta J, Belongia EA, McLean HQ, Kim S, Patel MM, Chung JR

Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022.
(2022 Nov)
Influenza Other Respir Viruses 16(6): 975-985
Kim SS, Chung JR, Talbot HK, Grijalva CG, Wernli KJ, Kiniry E, Martin ET, Monto AS, Belongia EA, McLean HQ, Gaglani M, Mamawala M, Nowalk MP, Moehling Geffel K, Tartof SY, Florea A, Lee JS, Tenforde MW, Patel MM, Flannery B, Strain Surveillance and Emerging Variants Team, Bentz ML, Burgin A, Burroughs M, Davis ML, Howard D, Lacek K, Madden JC, Nobles S, Padilla J, Sheth M

Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status.
(2023 Apr 15)
Cancer 129(8): 1173-1182
Lowry KP, Ichikawa L, Hubbard RA, Buist DSM, Bowles EJA, Henderson LM, Kerlikowske K, Specht JM, Sprague BL, Wernli KJ, Lee JM

Show complete publication list